Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Busulfan in Anemia, Sickle Cell: NCT06399107 Clinical Landscape Report 2026
28 September 2026
NCT06399107 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Prednisolone Acetate in Myasthenia Gravis: TCTR20240515008 Clinical Landscape Report 2026
28 September 2026
TCTR20240515008 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zilucoplan in Myasthenia Gravis: NCT06435312 Clinical Landscape Report 2026
28 September 2026
NCT06435312 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Aspirin in Obstetric Labor, Premature: NCT06417411 Clinical Landscape Report 2026
28 September 2026
NCT06417411 clinical landscape for Obstetric Labor, Premature: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Taladegib in Idiopathic Pulmonary Fibrosis: NCT06422884 Clinical Landscape Report 2026
28 September 2026
NCT06422884 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bromophenoxyazole Propanoic Acid in Myasthenia Gravis: NCT06414954 Clinical Landscape Report 2026
28 September 2026
NCT06414954 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GC-012F in Myasthenia Gravis: NCT06419166 Clinical Landscape Report 2026
28 September 2026
NCT06419166 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Motixafortide in Semicircular Canal Dehiscence: NCT06442761 Clinical Landscape Report 2026
28 September 2026
NCT06442761 clinical landscape for Semicircular Canal Dehiscence: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sugammadex Sodium in Reversal of Neuromuscular Blockade: NCT06436768 Clinical Landscape Report 2026
28 September 2026
NCT06436768 clinical landscape for Reversal of Neuromuscular Blockade: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Crizanlizumab-TMCA in Vaso-occlusive crisis: NCT06439082 Clinical Landscape Report 2026
28 September 2026
NCT06439082 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) in Myasthenia Gravis: NCT06447597 Clinical Landscape Report 2026
28 September 2026
NCT06447597 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Desidustat in Hemoglobin SC Disease: CTRI/2024/06/068363 Clinical Landscape Report 2026
28 September 2026
CTRI/2024/06/068363 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.